Viral Conjunctivitis Pipeline Drugs Market size is expected to grow at a CAGR of 3.79% throughout the forecast period, reaching nearly US$ 4.73 Bn. by 2029.Viral Conjunctivitis Pipeline Drugs Market Drivers and Restrains:
Viral Conjunctivitis is known as pinkeye. It is a highly contagious acute conjunctiva infection usually caused by adenovirus. Several viruses that can cause conjunctival infection depend on herpes simplex virus (HSV), varicella-zoster virus (VZV), picornavirus (enterovirus 70, Coxsackie A24), poxvirus (molluscumcontagiosum, vaccinia). Some of the symptoms of viral conjunctivitis contain light sensitivity, tearing, itchy eyes and redness. The transmission may also occur through accidental inoculation of viral particles from patient’s hands, contaminated swimming pools as well as by contact from droplets of infected upper respiratory tracks.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report The viral conjunctivitis pipeline drugs market driven by the factors are accessibility of diagnostic test, rising awareness, increasing healthcare expenditure, and increased R&D activities. Viral conjunctivitis is one of the major causes of infectious consequently increasing the demand of the viral conjunctivitis pipeline drugs. Various countries like U.S., Germany, Australia, Brazil and Japan has greater occurrence rate of viral conjunctivitis. Viral conjunctivitis therapeutics is undergoing a transitional phase. Now, there is no drug existing for the treatment of viral conjunctivitis. High cost, appropriate diagnosis, and less awareness regarding advance technologies are major restraining factors of the market growth at global. Investment in rigorous R&D activities and strengthen commercialization activities are provided to lucrative opportunity for the key companies of the viral conjunctivitis pipeline drug market. Viral Conjunctivitis Pipeline Drugs Market Segmentation Analysis: Based on the drug, the viral conjunctivitis pipeline drugs has been segmented into APD-209 and FST-100. FST-100 segment held the dominant share of the viral conjunctivitis pipeline drugs market during the forecast period. The development of this drug was being developed by Foresight Biotherapeutics Inc. originated the development of treatment and therapies in ophthalmology and otolaryngology such as the FST-100. Approved drugs are considered as one of the premium medication for the treatment of bacterial and viral eye infection. This is likely to offer potential growth opportunities in the upcoming period. Furthermore, APD-209 segment is expected to grow at the largest CAGR of xx% during the forecast period follows by FST-100. Adenovir Pharma AB is the company to develop APD-209 and is undergoing phase II clinical trial.
Viral Conjunctivitis Pipeline Drugs Market Regional Analysis:
Geographically, the viral conjunctivitis pipeline drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the viral conjunctivitis pipeline drugs market in 2018 due to the rising contribution from the U.S. The rising R&D activities and the increasing focus on novelties are some of the key factors that are estimated to encourage the North America market growth during the forecast period. The market in Europe is expected to expand at a high CAGR of xx% during the forecast period followed by Asia Pacific. The rising awareness between people associated with the eye-disorders is considered as one of the vital factors anticipated to boost the growth of the Europe market in the near future.Viral Conjunctivitis Pipeline Drugs Market Competitive landscape
Major Key players operating in this market are Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd. Manufacturers in the viral conjunctivitis pipeline drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present comprehensive analysis of viral conjunctivitis pipeline drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding viral conjunctivitis pipeline drugs market dynamics, structure by analyzing the market segments, and project the viral conjunctivitis pipeline drugs market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the viral conjunctivitis pipeline drugs market make the report investor’s guide.Viral Conjunctivitis Pipeline Drugs Market Scope : Inquire before buying
Viral Conjunctivitis Pipeline Drugs Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2017 to 2022 Market Size in 2022: US $ 3.65 Bn. Forecast Period 2023 to 2029 CAGR: 3.79% Market Size in 2029: US $ 4.73 Bn. Segments Covered: by Drugs • DST-100 • APD-209 by Distribution Channel • Hospital Pharmacies • Retail pharmacies • Online pharmacies Viral Conjunctivitis Pipeline Drugs Market by Region
• North America (United States, Canada and Mexico) • Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) • Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) • Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) • South America (Brazil, Argentina Rest of South America)Viral Conjunctivitis Pipeline Drugs Market, Major Players:
• Adenovir Pharma AB • Allergan plc • NanoViricides, Inc. • Shire plc • NovaBay Pharmaceuticals, Inc. • Novartis AG • Panoptes Pharma GES.M.B.H. • NicOx S.A. • KinoPharma • Aldeyra • Takeda • Sylentis • Dermira • Marinomed Biotech GmbH • Starpharma Holdings Ltd. Frequently Asked Questions: 1. Which region has the largest share in Global Viral Conjunctivitis Pipeline Drugs Market? Ans: North America region held the highest share in 2022. 2. What is the growth rate of Global Viral Conjunctivitis Pipeline Drugs Market? Ans: The Global Viral Conjunctivitis Pipeline Drugs Market is growing at a CAGR of 3.79% during forecasting period 2023-2029. 3. What is scope of the Global Viral Conjunctivitis Pipeline Drugs Market report? Ans: Global Viral Conjunctivitis Pipeline Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Viral Conjunctivitis Pipeline Drugs Market? Ans: The important key players in the Global Viral Conjunctivitis Pipeline Drugs Market are – Adenovir Pharma AB,Allergan plc,NanoViricides, Inc.,Shire plc,NovaBay Pharmaceuticals, Inc.,Novartis AG,Panoptes Pharma GES.M.B.H.,NicOx S.A.,KinoPharma,Aldeyra,Takeda,Sylentis,Dermira,Marinomed Biotech GmbH,Starpharma Holdings Ltd. 5. What is the study period of this Market? Ans: The Global Viral Conjunctivitis Pipeline Drugs Market is studied from 2022 to 2029.
Viral Conjunctivitis Pipeline Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Viral Conjunctivitis Pipeline Drugs Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Viral Conjunctivitis Pipeline Drugs Market Analysis and Forecast 6.1. Global Viral Conjunctivitis Pipeline Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Viral Conjunctivitis Pipeline Drugs Market Analysis and Forecast, by Drugs 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Drugs 7.4. Global Viral Conjunctivitis Pipeline Drugs Market Size (US$ Mn) Forecast, by Drugs 7.5. Global Viral Conjunctivitis Pipeline Drugs Market Analysis, by Drugs 7.6. Global Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis, by Drugs 8. Global Viral Conjunctivitis Pipeline Drugs Market Analysis and Forecast, by Distribution Channel 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Distribution Channel 8.4. Global Viral Conjunctivitis Pipeline Drugs Market Size (US$ Mn) Forecast, by Distribution Channel 8.5. Global Viral Conjunctivitis Pipeline Drugs Market Analysis, by Distribution Channel 8.6. Global Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis, by Distribution Channel 9. Global Viral Conjunctivitis Pipeline Drugs Market Analysis, by Region 9.1. Global Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Region 9.2. Global Viral Conjunctivitis Pipeline Drugs Market Size (US$ Mn) Forecast, by Region 9.3. Global Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis, by Region 10. North America Viral Conjunctivitis Pipeline Drugs Market Analysis 10.1. Key Findings 10.2. North America Viral Conjunctivitis Pipeline Drugs Market Overview 10.3. North America Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Drugs 10.4. North America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 10.4.1. DST-100 10.4.2. APD-209 10.5. North America Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Distribution Channel 10.6. North America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 10.6.1. Hospital Pharmacies 10.6.2. Retail pharmacies 10.6.3. Online pharmacies 10.7. North America Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Country 10.8. North America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Viral Conjunctivitis Pipeline Drugs Market Analysis, by Country 10.10. U.S. Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 10.10.1. DST-100 10.10.2. APD-209 10.11. U.S. Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 10.11.1. Hospital Pharmacies 10.11.2. Retail pharmacies 10.11.3. Online pharmacies 10.12. Canada Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 10.12.1. DST-100 10.12.2. APD-209 10.13. Canada Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 10.13.1. Hospital Pharmacies 10.13.2. Retail pharmacies 10.13.3. Online pharmacies 10.14. North America Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis 10.14.1. By Drugs 10.14.2. By Distribution Channel 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Viral Conjunctivitis Pipeline Drugs Market Analysis 11.1. Key Findings 11.2. Europe Viral Conjunctivitis Pipeline Drugs Market Overview 11.3. Europe Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Drugs 11.4. Europe Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.4.1. DST-100 11.4.2. APD-209 11.5. Europe Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Distribution Channel 11.6. Europe Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.6.1. Hospital Pharmacies 11.6.2. Retail pharmacies 11.6.3. Online pharmacies 11.7. Europe Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Country 11.8. Europe Viral Conjunctivitis Pipeline Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Viral Conjunctivitis Pipeline Drugs Market Analysis, by Country 11.10. Germany Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.10.1. DST-100 11.10.2. APD-209 11.11. Germany Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.11.1. Hospital Pharmacies 11.11.2. Retail pharmacies 11.11.3. Online pharmacies 11.12. U.K. Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.12.1. DST-100 11.12.2. APD-209 11.13. U.K. Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.13.1. Hospital Pharmacies 11.13.2. Retail pharmacies 11.13.3. Online pharmacies 11.14. France Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.14.1. DST-100 11.14.2. APD-209 11.15. France Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.15.1. Hospital Pharmacies 11.15.2. Retail pharmacies 11.15.3. Online pharmacies 11.16. Italy Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.16.1. DST-100 11.16.2. APD-209 11.17. Italy Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Retail pharmacies 11.17.3. Online pharmacies 11.18. Spain Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.18.1. DST-100 11.18.2. APD-209 11.19. Spain Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.19.1. Hospital Pharmacies 11.19.2. Retail pharmacies 11.19.3. Online pharmacies 11.20. Rest of Europe Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 11.20.1. DST-100 11.20.2. APD-209 11.21. Rest of Europe Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 11.21.1. Hospital Pharmacies 11.21.2. Retail pharmacies 11.21.3. Online pharmacies 11.22. Europe Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis 11.22.1. By Drugs 11.22.2. By Distribution Channel 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Overview 12.3. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Drugs 12.4. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 12.4.1. DST-100 12.4.2. APD-209 12.5. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Distribution Channel 12.6. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 12.6.1. Hospital Pharmacies 12.6.2. Retail pharmacies 12.6.3. Online pharmacies 12.7. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Analysis, by Country 12.10. China Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 12.10.1. DST-100 12.10.2. APD-209 12.11. China Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 12.11.1. Hospital Pharmacies 12.11.2. Retail pharmacies 12.11.3. Online pharmacies 12.12. India Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 12.12.1. DST-100 12.12.2. APD-209 12.13. India Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 12.13.1. Hospital Pharmacies 12.13.2. Retail pharmacies 12.13.3. Online pharmacies 12.14. Japan Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 12.14.1. DST-100 12.14.2. APD-209 12.15. Japan Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 12.15.1. Hospital Pharmacies 12.15.2. Retail pharmacies 12.15.3. Online pharmacies 12.16. ASEAN Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 12.16.1. DST-100 12.16.2. APD-209 12.17. ASEAN Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Retail pharmacies 12.17.3. Online pharmacies 12.18. Rest of Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 12.18.1. DST-100 12.18.2. APD-209 12.19. Rest of Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 12.19.1. Hospital Pharmacies 12.19.2. Retail pharmacies 12.19.3. Online pharmacies 12.20. Asia Pacific Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis 12.20.1. By Drugs 12.20.2. By Distribution Channel 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Overview 13.3. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Drugs 13.4. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 13.4.1. DST-100 13.4.2. APD-209 13.5. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Distribution Channel 13.6. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 13.6.1. Hospital Pharmacies 13.6.2. Retail pharmacies 13.6.3. Online pharmacies 13.7. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Analysis, by Country 13.10. GCC Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 13.10.1. DST-100 13.10.2. APD-209 13.11. GCC Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 13.11.1. Hospital Pharmacies 13.11.2. Retail pharmacies 13.11.3. Online pharmacies 13.12. South Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 13.12.1. DST-100 13.12.2. APD-209 13.13. South Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 13.13.1. Hospital Pharmacies 13.13.2. Retail pharmacies 13.13.3. Online pharmacies 13.14. Rest of Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 13.14.1. DST-100 13.14.2. APD-209 13.15. Rest of Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 13.15.1. Hospital Pharmacies 13.15.2. Retail pharmacies 13.15.3. Online pharmacies 13.16. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis 13.16.1. By Drugs 13.16.2. By Distribution Channel 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Viral Conjunctivitis Pipeline Drugs Market Analysis 14.1. Key Findings 14.2. South America Viral Conjunctivitis Pipeline Drugs Market Overview 14.3. South America Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Drugs 14.4. South America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 14.4.1. DST-100 14.4.2. APD-209 14.5. Others South America Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Distribution Channel 14.6. South America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 14.6.1. Hospital Pharmacies 14.6.2. Retail pharmacies 14.6.3. Online pharmacies 14.7. South America Viral Conjunctivitis Pipeline Drugs Market Value Share Analysis, by Country 14.8. South America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 14.9.1. DST-100 14.9.2. APD-209 14.10. Brazil Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 14.10.1. Hospital Pharmacies 14.10.2. Retail pharmacies 14.10.3. Online pharmacies 14.11. Mexico Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 14.11.1. DST-100 14.11.2. APD-209 14.12. Mexico Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 14.12.1. Hospital Pharmacies 14.12.2. Retail pharmacies 14.12.3. Online pharmacies 14.13. Rest of South America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Drugs 14.13.1. DST-100 14.13.2. APD-209 14.14. Rest of South America Viral Conjunctivitis Pipeline Drugs Market Forecast, by Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Retail pharmacies 14.14.3. Online pharmacies 14.15. South America Viral Conjunctivitis Pipeline Drugs Market Attractiveness Analysis 14.15.1. By Drugs 14.15.2. By Distribution Channel 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Adenovir Pharma AB 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Allergan plc 15.3.3. NanoViricides, Inc. 15.3.4. Shire plc 15.3.5. NovaBay Pharmaceuticals, Inc. 15.3.6. Novartis AG 15.3.7. Panoptes Pharma GES.M.B.H. 15.3.8. NicOx S.A. 15.3.9. KinoPharma 15.3.10. Aldeyra 15.3.11. Takeda 15.3.12. Sylentis 15.3.13. Dermira 15.3.14. Marinomed Biotech GmbH 15.3.15. Starpharma Holdings Ltd. 16. Primary Key Insights